East Windsor, NJ—Sabinsa’s Curcumin C3 Complex has been studied in a phase IIa trial as an adjuvant therapy with FOLFOX chemotherapy, according to a press release, and results suggest that using curcumin with FOLFOX could provide a safe and tolerable treatment with potential to provide patient benefit.
In the study, which was published in the Journal of Nutrition, 27 subjects with metastatic colorectal cancer were randomized to take FOLFOX or FOLFOX+Curcumin C3 Complex (CUFOX). Median progression-free survival was 171 days for FOLFOX and 320 days for CUFOX; median overall survival was 200 days for FOLFOX and 596 days for CUFOX.
N. Kalyanam, Ph.D., president of R&D and Sabinsa, said in the release: “Research examining the use of drugs and nutraceuticals together is an exciting new direction to investigate. Sabinsa continues to build on science and contribute to the extensive knowledge base of curcumin for better health for all.”
The study can be found here.